Evaluation of asymptomatic bacteriuria and urinary tract infections in Egyptian rheumatoid arthritis patients using biological and /or conventional DMARDs
Keywords:
rheumatoid arthritis, asymptomatic bacteriuria, urinary tract infection, disease modifying antirheumatic drugsAbstract
Objective: To determine how frequently Egyptian RA patients receiving biological and/or traditional DMARDs experience asymptomatic bacteriuria and urinary tract infections (UTI). Methods: 100 RA patients and 100 age- and sex-matched healthy controls made up this cross-sectional study. For urine analysis and culture, each participant provided mid-stream urine sample. Each participant's blood was drawn for ELISA testing to measure the levels of IgG antibodies against Proteus mirabilis and E. coli, the most frequently isolated pathogen from RA patients’ urine samples. Additionally, RA patients' clinical assessments were carried out. Results: (5%) of healthy controls and (40%) of RA patients had asymptomatic bacteriuria, respectively. E. coli (25%), followed by Proteus mirabilis (42.5%), were the two most frequently isolated organisms. IgG antibody levels against Proteus mirabilis were significantly different between the two study groups (P 0.001). Regarding the levels of IgG antibodies against E. coli, there was no discernible difference between the two study groups (P 0.571). Proteus mirabilis IgG antibody levels were observed to significantly positively correlate with ESR, CRP, DAS28, m HAQ, duration of morning stiffness, and conventional DMARDs in RA patients.
Downloads
References
Croia C, Bursi R, Sutera D, Petrelli F, Alunno A, Puxeddu I. One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37:347-57.
Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. Autoimmun Rev. 2010;9:216-23.
Li S, Yu Y, Yue Y, Zhang Z, Su K. Microbial Infection and Rheumatoid Arthritis. J Clin Cell Immunol. 2013;4.
Pretorius E, Akeredolu OO, Soma P, Kell DB. Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. Exp Biol Med (Maywood). 2017;242:355-73.
Senior BW, Anderson GA, Morley KD, Kerr MA. Evidence that patients with rheumatoid arthritis have asymptomatic 'non-significant' Proteus mirabilis bacteriuria more frequently than healthy controls. J Infect. 1999;38:99-106.
Schaffer JN, Pearson MM. Proteus mirabilis and Urinary Tract Infections. Microbiol Spectr. 2015;3.
Dielubanza EJ, Schaeffer AJ. Urinary tract infections in women. Med Clin North Am. 2011;95:27-41.
Hayami H, Takahashi S, Ishikawa K, Yasuda M, Yamamoto S, Uehara S, et al. Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus. J Infect Chemother. 2013;19:393-403.
Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643-54.
Cock I. The early stages of rheumatoid arthritis: New targets for the development of combinational drug therapies. OA Arthritis. 2014;2:5.
Christopoulos G, Christopoulou V, Routsias JG, Babionitakis A, Antoniadis C, Vaiopoulos G. Greek rheumatoid arthritis patients have elevated levels of antibodies against antigens from Proteus mirabilis. Clin Rheumatol. 2017;36:527-35.
Al Kady LM, El Toukhy MAEH, El Shafie MAER, Mohammed HAEA, Mohammed Saber NI. Asymptomatic urinary tract infection by proteus mirabilis in rheumatoid arthritis patients. Zagazig University Medical Journal. 2019;25:928-34.
Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010;62:2582-91.
van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:S40-s4.
Ono K, Ohashi S, Oka H, Kadono Y, Yasui T, Omata Y, et al. The impact of joint disease on the Modified Health Assessment Questionnaire scores in rheumatoid arthritis patients: A cross-sectional study using the National Database of Rheumatic Diseases by iR-net in Japan. Mod Rheumatol. 2016;26:529-33.
Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci. 2004;34:423-6.
Seringec Akkececi N, Yildirim Cetin G, Gogebakan H, Acipayam C. The C-Reactive Protein/Albumin Ratio and Complete Blood Count Parameters as Indicators of Disease Activity in Patients with Takayasu Arteritis. Med Sci Monit. 2019;25:1401-9.
De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004;63:1587-93.
Forbes BA, Sahm DF, Weissfeld AS. Study Guide for Bailey and Scott's Diagnostic Microbiology-E-Book: Elsevier Health Sciences; 2016.
Kotulska A, Kucharz EJ, Wiland P, Olesińska M, Felis-Giemza A, Kopeć-Mędrek M, et al. Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. Reumatologia. 2018;56:140-8.
Calabresi E, Petrelli F, Bonifacio AF, Puxeddu I, Alunno A. One year in review 2018: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2018;36:175-84.
Georgiadou SP, Gamaletsou MN, Mpanaka I, Vlachou A, Goules AV, Ziogas DC, et al. Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance. Clin Infect Dis. 2015;60:868-74.
Devaki R, Kandi V, Veeramachaneni R, Indurkar PS. Evaluation of anti-bacterial IgG antibodies among rheumatoid arthritis and non rheumatoid arthritis patients with special reference to anti Proteus antibodies. International Journal of Research in Medical Sciences. 2016;4:628.
Wilson C, Rashid T, Ebringer A. Worldwide links between proteus mirabilis and rheumatoid arthritis. Journal of Arthritis. 2015;4:1-7.
Rashid T, Ebringer A. Rheumatoid arthritis is linked to Proteus--the evidence. Clin Rheumatol. 2007;26:1036-43.
Wilson C, Rashid T, Tiwana H, Beyan H, Hughes L, Bansal S, et al. Cytotoxicity responses to peptide antigens in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2003;30:972-8.
Guilherme L, Köhler KF, Kalil J. Rheumatic heart disease: mediation by complex immune events. Adv Clin Chem. 2011;53:31-50.
Deighton CM, Gray J, Bint AJ, Walker DJ. Specificity of the proteus antibody response in rheumatoid arthritis. Ann Rheum Dis. 1992;51:1206-7.
Ebringer A, Rashid T. Rheumatoid arthritis is caused by a Proteus urinary tract infection. Apmis. 2014;122:363-8.
Chandrashekara S, Patil R, Vadiraja HS, Shobha A. The incidence of Proteus mirabilis infection increases in patients on treatment but does not trigger disease activity. Clin Rheumatol. 2006;25:520-3.
Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368-76.
Attar A, Suzan M, Al Ghamdi A. Rate of Infection in Rheumatoid Arthritis Patients. Saudi J Int Med. 2014;41:15-21.
Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med. 2014;12:77.
Arshad A, Rashid R. The prevalence of bronchopulmonary infection among patients with rheumatoid arthritis versus non rheumatoid arthritis patients. Malays J Med Sci. 2008;15:24-8.
Kolls JK, Lei D, Vazquez C, Odom G, Summer WR, Nelson S, et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol. 1997;16:112-8.
Aldauig BA, Alshehri KA, Alharbi AA, Bajaba RM, Alghamdi S, Attar S. The Prevalence of Infection in RA Patients using Biological DMARDs in King Abdul-Aziz University Hospital Jeddah, Saudi Arabia: A cross sectional study. The Egyptian Journal of Hospital Medicine. 2018;72:4349-54.
Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403-12.
Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327-46.
Published
How to Cite
Issue
Section
Copyright (c) 2021 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
